Tiziana Life Sciences doses first patients in Phase 2a intranasal foralumab ALS trial
Bitget2026/09/28 11:00- Tiziana Life Sciences dosed the first three participants in a Phase 2a trial of intranasal foralumab in ALS.
- No results have been presented; the study is designed to generate safety data and biomarker signals over a 24-week treatment plan.
- Primary readout targets tolerability, with secondary measures aimed at showing immune modulation with potential relevance to neuroinflammation.
- Trial enrollment targets 44 early-stage ALS patients, using a 3:1 randomization between active drug and placebo.
- Program funding includes support from the ALS Association, positioning the asset for a clearer go/no-go decision on further development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synopsys (SNPS.US) partners with OpenAI to develop AI models for chip design, revenue-sharing model drives stock price up by 7%
On Wednesday, chip design software provider Synopsys (SNPS.US) announced that it has reached a partnership agreement with OpenAI. Both parties will jointly develop AI models for the chip business and share related revenues.
BoJ Summary of Opinions: Member says appropriate to keep raising rates in line with economy, price
Rio Tinto secures Bell Bay aluminum smelter operations till 2031
The British Pound rallies on a UK growth upgrade and gives more than half back
Crypto prices
More
